Lockett named KCBJ 2015 CFO of the Year - nonprofits

General published Fri, 2015-04-17 16:31

Financial executives are instrumental to the success of their company but are not always celebrated.  To recognize the unsung position, the Kansas City Business Journal's 2015 CFO of the Year were announced today.

KBA CFO & COO, Kevin Lockett, was named 2015 KCBJ CFO of the Year in the nonprofit category.  Congratulations Kevin!



Integrated Animal Health to locate global HQ in Kansas

Animal Health published Mon, 2015-04-13 14:13

Following a February announcement that it would locate its North American and commercial operations in the KC Animal Health Corridor, Australia-based Integrated Animal Health (IAH) announced today it will now locate its global headquarters at the Bioscience & Technology Business Center (BTBC) in Lawrence, Kansas. IAH will initially lease 700 sq. ft. at the BTBC at the University of Kansas, with options to expand as the company grows. The company expects to hire 51 employees over the next several years.

Read the story here.



Proteon founder Franano links InvestMidwest's past and future

Human Health published Fri, 2015-04-03 11:03

- by Rob Roberts, Kansas City Business Journal.

Dr. Nick Franano, the breakfast speaker at the 16th-annual InvestMidwest Venture Capital Forum on Thursday, recalled presenting at the forum in 2003.

Like the biotech industry itself, Franano has come a long way since presenting that year for his then company, Proteon Therapeutics Inc. And, he said Thursday, the future is bright for other biotech companies that are able to raise enough venture capital to advance discoveries through successful clinical trials.

In the fourth quarter of 2014 alone, he said, more than $2 billion was invested in private U.S. biotech startups.

From January 2013 through February 2015, Franano added, 121 U.S. biotech firms completed IPOs, with 2014 generating the most biotech IPOs in history.

Franano attributed the rise in IPOs, in part, to the 2012 passage of the federal Jumpstart Our Business Startups, or JOBS, Act. Among other things, the act allows startups designated as "emerging growth companies" to test the IPO waters confidentially by getting investor and Securities and Exchange Commission feedback before filing public registration documents.

Franano knows about IPOs and bright futures. When he first pitched at InvestMidwest in 2003, he was founder and CEO of Proteon Therapeutics, then a 2-year-old Kansas City company that had raised about $5 million to develop a drug Franano discovered during a residency at Johns Hopkins University in Baltimore.


Read the full Kansas City Business Journal article here.

- photo credit: Rob Roberts